However, its important to note that while these GLP-1 receptor agonists are highly effective, they may not be suitable for everyone
In this trial, individuals who received Semaglutide dropped approximately 6.2 % of their primary bodyweight against those who received a placebo
Appetite & satiety: In non-diabetic obesity, a phase 2 dose-escalation study reported progressive, dose-related body-weight reduction, consistent with central amylin satiety signaling [5]
However, these results are mainly obtained from lifestyle and surgical weight loss strategies, and the mechanism of weight regain after AOM discontinuation needs to be further explored
GLP-1 drugs and their labeling and regulatory history relevant to NAION
Shima Hadidchi for Weight Loss and Oral Semaglutide Treatment